L Fischer von Weikersthal
Overview
Explore the profile of L Fischer von Weikersthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meren S, Josfeld L, Bahlmann J, Fischer von Weikersthal L, Mannle H, Huebner J
Palliat Support Care
. 2025 Jan;
23():e21.
PMID: 39829247
Objectives: This study aimed to investigate the influence of feelings of guilt among cancer patients on their health behavior, with a specific focus on the use of complementary and alternative...
2.
Alig A, Modest D, Stintzing S, Heinrich K, Geissler M, Fischer von Weikersthal L, et al.
ESMO Open
. 2024 Aug;
9(9):103677.
PMID: 39173562
Background: Primary tumor (PT) sidedness is an established prognostic marker in metastatic colorectal cancer (mCRC) and has a predictive impact on the efficacy of anti-epidermal growth factor receptor (anti-EGFR) antibody...
3.
Boukovala M, Modest D, Ricard I, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al.
ESMO Open
. 2024 May;
9(5):103374.
PMID: 38744100
Background: The inflammation-based modified Glasgow Prognostic Score (mGPS) combines serum levels of C-reactive protein and albumin and was shown to predict survival in advanced cancer. We aimed to elucidate the...
4.
Heinrich K, Karthaus M, Fruehauf S, Graeven U, Mueller L, Konig A, et al.
ESMO Open
. 2023 Jul;
8(4):101568.
PMID: 37441876
Background: Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespective of sex. Sex-associated differences relating to safety and efficacy in the treatment of mCRC, however, are gaining interest....
5.
Bargehr B, Fischer von Weikersthal L, Junghans C, Zomorodbakhsch B, Stoll C, Prott F, et al.
J Cancer Res Clin Oncol
. 2023 Apr;
149(11):8393-8402.
PMID: 37079052
Purpose: For patients with a cancer diagnosis, coping abilities are of high importance. Cancer patients with a high sense of coherence may cope better. The purpose of this study is...
6.
Festerling L, Buentzel J, Fischer von Weikersthal L, Junghans C, Zomorodbakhsch B, Stoll C, et al.
J Cancer Res Clin Oncol
. 2022 Nov;
149(8):5279-5287.
PMID: 36396875
Background: Being diagnosed with cancer is challenging. Many patients wish to be actively involved in treatment and contribute to therapy, but the patients' coping abilities and desire for involvement differ....
7.
Sommerhauser G, Kurreck A, Stintzing S, Heinemann V, Fischer von Weikersthal L, Dechow T, et al.
BMC Cancer
. 2022 Jul;
22(1):820.
PMID: 35897060
Background: Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined...
8.
Haas M, Waldschmidt D, Stahl M, Reinacher-Schick A, Freiberg-Richter J, Fischer von Weikersthal L, et al.
Eur J Cancer
. 2021 Feb;
146:95-106.
PMID: 33588150
Background: Targeting the epidermal growth factor receptor pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non-small-cell lung cancer. This open-label, multicenter, randomised...
9.
Holch J, Held S, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Ann Oncol
. 2020 Jan;
31(1):72-78.
PMID: 31912799
Background: Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for targeted therapy, we investigated its prognostic impact with early tumor...
10.
Stintzing S, Wirapati P, Lenz H, Neureiter D, Fischer von Weikersthal L, Decker T, et al.
Ann Oncol
. 2019 Dec;
30(11):1796-1803.
PMID: 31868905
Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping...